CSS
ATXS

Cubist Systematic Strategies’s Astria Therapeutics ATXS Stock Holding History

Cubist Systematic Strategies’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$525K Buy
72,077
+34,904
+94% +$236K ﹤0.01% 2260
2025
Q2 		$199K Sell
37,173
-55,066
-60% -$267K ﹤0.01% 2601
2025
Q1 		$493K Buy
92,239
+76,961
+504% +$538K ﹤0.01% 2170
2024
Q4 		$137K Buy
+15,278
New +$162K ﹤0.01% 2657
2024
Q3 		– Sell
-281,410
Closed -$2.56M – 2976
2024
Q2 		$2.56M Buy
+281,410
New +$2.75M 0.02% 1173
2023
Q2 		– Sell
-17,363
Closed -$231K – 3488
2023
Q1 		$231K Sell
17,363
-6,099
-26% -$82.5K ﹤0.01% 3155
2022
Q4 		$349K Buy
23,462
+8,796
+60% +$90.7K ﹤0.01% 3264
2022
Q3 		$133K Buy
+14,666
New +$98.3K ﹤0.01% 3923

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Cubist Systematic Strategies's ATXS Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Astria Therapeutics (ATXS) stake by 94% in Q3 2025, buying an estimated $236K and bringing the position to 72,077 shares worth $525K. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Cubist Systematic Strategies first reported a position in ATXS in Q3 2022 and has held it in 8 quarters since. The position peaked at $2.56M in Q2 2024. 115 funds tracked by Wall St. Rank hold ATXS as of Q3 2025.

  • Cubist Systematic Strategies held 72,077 shares of Astria Therapeutics worth $525K as of Q3 2025.
  • Cubist Systematic Strategies bought 34,904 Astria Therapeutics shares in Q3 2025, an estimated $236K.
  • Astria Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2260 holding.
  • Cubist Systematic Strategies first reported a position in Astria Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • Cubist Systematic Strategies's Astria Therapeutics position peaked at $2.56M in Q2 2024.
  • 115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.